GFAP and amyotrophic lateral sclerosis: Reducing levels of pro-inflammatory proteins such as CHGA and GFAP could be therapeutic for ALS and biomarkers such as APP, MAPT, and neurofilaments could confirm if filtration is modifying ALS progression meaningfully.